Thus, a patient’s response to treatment cannot depend solely on the levels of a biomarker such as BDNF and its polymorphisms; instead, they should be incorporated into a larger MDD scoring system that could integrate an individual’s biological, ethnic, social and psychological characteristics, offering together a much more accurate prognosis predictor for potential therapeutic approaches. The gene discussed is BDNF; the disease is major depressive disorder.